Vicore completes ASPIRE enrollment, adds US listing and new CSO in Q2 2026

Vicore Pharma Holding AB reported its second-quarter 2026 results on August 21, 2026, covering the period from April 1 to June 30, 2026.

The company said in April it completed patient recruitment in the Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis, enrolling more than 360 patients across over 100 sites in 14 countries, with recruitment completed ahead of schedule and topline results expected mid-2027.¹

After the quarter closed, Vicore's American Depositary Shares began trading on Nasdaq Capital Market under the ticker "VCRE," described by the company as "a dual listing that complements Vicore's existing listing on Nasdaq Stockholm under the ticker symbol 'VICO.'"¹ Each ADS represents 10 common shares, no par value, with ISIN code US92581R1041.¹

Also in July, the company announced the appointment of Rob Slack, PhD, FRSB, as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will transition to the role of Senior Advisor.¹

Financially, net revenues were SEK 2.2 million versus SEK 1.7 million a year earlier, while operating loss widened to SEK 150.1 million from SEK 111.2 million for the three months ended June 30.¹ Loss per share was SEK 0.51 compared with SEK 0.49 in the prior-year quarter.¹

Cash, cash equivalents, and short-term investments stood at SEK 905.6 million (USD 93.0 million) as of June 30, 2026, down from SEK 1,166.7 million (USD 126.8 million) at year-end 2025.¹ The CEO said the company's cash runway extends into the second half of 2028, providing financial visibility through the mid-2027 readout.¹

Vicore's next reporting date is set for November 5, 2026 for the Q3 interim report, and February 25, 2027 for the year-end report.¹